Revotar receives new composition-of-matter patent for Bimosiamose in the US
(Thomson Reuters ONE) -
Revotar Biopharmaceuticals AG /
Revotar receives new composition-of-matter patent for Bimosiamose in the US
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
BERLIN/Hennigsdorf (Germany), November 2(nd), 2011 - Revotar Biopharmaceuticals
AG today announced that it has been granted a strategically important patent on
a novel crystalline form of its pan-selectin antagonist Bimosiamose by the US
Patent & Trademark Office (USPTO). This patent ("Crystalline Forms of 1,6-
Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyloxy)-phenyl] hexane",
US 8,039,601) covers a new polymorph form of the pan-selectin antagonist and
pharmaceutical compositions and complements the patent portfolio which Revotar
is holding around this important product for the treatment of COPD and other
chronic and acute respiratory diseases. It generates further composition-of-
matter for Bimosiamose and enhances the existing protection of the drug. "For
the life cycle of Revotar's most advanced drug candidate Bimosiamose on the US
market the issuance of this patent is of strategic importance as it extends the
protection of the compound beyond the existing intellectual property rights
until 2027", comments Dr. Martin Pöhlchen, CEO of Revotar. "We also believe that
this patent qualifies as a basis for a patent term extension up to five years
beyond 2027", he added.
About COPD
Chronic Obstructive Pulmonary Disease (COPD) comprises several serious
conditions affecting the lung. According to the WHO, estimated 64 million people
have COPD worldwide in 2004. More than 3 million people died of COPD in 2005,
which corresponds to 5% of all deaths globally. The WHO predicts that COPD will
become the third leading cause of death worldwide by 2030. In 2010, the global
COPD market recorded sales of approximately 11 billion US$. There is a high
unmet medical need in drugs modifying the underlying inflammation in COPD.
About Revotar Biopharmaceuticals AG
Revotar recently announced that it successfully completed a multi-center Phase
II trial to evaluate the safety and efficacy of inhaled Bimosiamose for the
treatment of patients with chronic obstructive pulmonary disease (COPD).
Data have been presented in the late breaking news session at the recent annual
congress of the European Respiratory Society (ERS) in Amsterdam end of September
and were presented by the research group of Prof. Helgo Magnussen. As previously
released, inhalation of Bimosiamose for 28 days on top of standard
bronchodilators was safe and well tolerated in 77 patients with moderate to
severe COPD (GOLD II-III). It led to a broad and significant attenuation of
airway inflammation and a trend towards lung function improvement.
Revotar develops innovative drugs for inflammatory indications such as chronic
obstructive pulmonary disease (COPD), acute lung injury (ALI) and asthma. Its
lead candidate Bimosiamose, a pan-selectin antagonist, has already passed
several clinical phase I and phase IIa trials in COPD, asthma, and psoriasis
with a good safety and efficacy profile in over 300 patients and volunteers.
Furthermore Revotar has two preclinical programs addressing respiratory and
other inflammatory diseases.
Contact Address:
Dr Martin Pöhlchen, CEO
Revotar Biopharmaceuticals AG
Neuendorfstr. 24a
D-16761 Hennigsdorf / Germany
Phone: +49-3302-2025010
Fax: +49-3302-2025030
Email:info(at)revotar.com
www.revotar.com
--- End of Message ---
Revotar Biopharmaceuticals AG
Neuendorfstr. 24a Hennigsdorf Germany
Press Release (PDF) :
http://hugin.info/143207/R/1560083/482566.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Revotar Biopharmaceuticals AG via Thomson Reuters ONE
[HUG#1560083]
Unternehmensinformation / Kurzprofil:
Datum: 02.11.2011 - 09:56 Uhr
Sprache: Deutsch
News-ID 82898
Anzahl Zeichen: 4665
contact information:
Town:
Hennigsdorf
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 243 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Revotar receives new composition-of-matter patent for Bimosiamose in the US"
steht unter der journalistisch-redaktionellen Verantwortung von
Revotar Biopharmaceuticals AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
